Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Efsubaglutide Alfa

Stage Phase 2/3Stale

Sponsor Shanghai Yinnuo Pharmaceutical Technology Co

Route injection

Class GLP-1 RA

Mechanism long-acting GLP-1 receptor agonist

Sources

registry, as of 2026-01-30Stale

https://clinicaltrials.gov/study/NCT06921486

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 1003. Conditions Obesity and Overweight. This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoin

ClinicalTrials.gov NCT06921486 protocol and results modules

registry, as of 2025-12-02Stale

https://clinicaltrials.gov/study/NCT07114419

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE). Overall status RECRUITING. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 200. Conditions Obesity and Overweight. This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, w

ClinicalTrials.gov NCT07114419 protocol and results modules

registry, as of 2025-04-02Stale

https://clinicaltrials.gov/study/NCT06732960

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 50. Conditions Overweight or Obesity. This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.

ClinicalTrials.gov NCT06732960 protocol and results modules

registry, as of 2026-01-27Stale

https://clinicaltrials.gov/study/NCT07163650

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery. Overall status RECRUITING. Phases PHASE4. Lead sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Enrollment 60. Conditions Obesity; Weight Loss; Metabolic Surgery. This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.

ClinicalTrials.gov NCT07163650 protocol and results modules

registry, as of 2026-07-30Stale

https://clinicaltrials.gov/study/NCT07693426

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents. Overall status RECRUITING. Phases PHASE1. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 36. Conditions Adolescence Obesity. This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with ob

ClinicalTrials.gov NCT07693426 protocol and results modules

publication, as of 2026-10-13Stale

https://pubmed.ncbi.nlm.nih.gov/42870102/

Efsubaglutide Alfa: A Comprehensive Pharmacological Review. Efsubaglutide alfa (also known as supaglutide) is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) engineered as a GLP-1 analogue fused to a human immunoglobulin G2 (IgG2) fragment crystallisable (Fc) domain. This narrative review summarises published and publicly ava

PMID 42870102

Studies

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Registry NCT06921486

Phase Phase 2/3

Status Active, not recruiting

Enrollment 1003

Start 2025-03-31

Primary completion 2026-08-31

Study completion 2026-12-31

Catalyst Primary completion. 2026-08-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Phase IIb:Efsubaglutide Alfa 5 mg QW

Dose 5 mg

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase IIb:Efsubaglutide Alfa 10 mg QW

Dose 10 mg

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase IIb:Efsubaglutide Alfa 20 mg QW

Dose 20 mg

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase IIb:Efsubaglutide Alfa 20 mg Q2W

Dose 20 mg

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase IIb:Placebo

Regimen once weekly

Weeks 3

Population Obesity and Overweight

Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W

Regimen once weekly

Weeks 3

Comparator placebo

Population Obesity and Overweight

Phase III:Placebo

Regimen once weekly

Weeks 3

Population Obesity and Overweight

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

Registry NCT07114419

Phase Phase 2

Status Recruiting

Enrollment 200

Start 2025-08-25

Primary completion 2026-06-01

Study completion 2026-08-01

Catalyst Primary completion. 2026-06-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Efsubaglutide 20 mg Quaque Week (QW)

Dose 20 mg

Regimen once weekly

Weeks 2

Population Obesity and Overweight

Efsubaglutide 40 mg QW

Dose 40 mg

Regimen once weekly

Weeks 2

Population Obesity and Overweight

Efsubaglutide Alfa 40 mg Q2W

Dose 40 mg

Regimen once weekly

Weeks 2

Population Obesity and Overweight

Efsubaglutide Alfa 80 mg QW

Dose 80 mg

Regimen once weekly

Weeks 2

Population Obesity and Overweight

Efsubaglutide Alfa 80 mg Q4W

Dose 80 mg

Regimen once weekly

Weeks 2

Population Obesity and Overweight

LIGHT

Registry NCT06732960

Phase Phase 2

Status Completed

Enrollment 50

Start 2024-04-21

Primary completion 2024-11-18

Study completion 2024-11-18

Efsubaglutide Alfa 5mg

Dose 5mg

Regimen once weekly

Weeks 4

Population Overweight or Obesity

Efsubaglutide Alfa 7.5mg

Dose 7.5mg

Regimen once weekly

Weeks 4

Population Overweight or Obesity

Efsubaglutide Alfa 10mg

Dose 10mg

Regimen once weekly

Weeks 4

Population Overweight or Obesity

Efsubaglutide Alfa 15mg

Dose 15mg

Regimen once weekly

Weeks 4

Population Overweight or Obesity

Efsubaglutide Alfa 20mg

Dose 20mg

Regimen once weekly

Weeks 4

Population Overweight or Obesity

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

Registry NCT07163650

Phase Phase 4

Status Recruiting

Enrollment 60

Start 2025-09-16

Primary completion 2026-11-30

Study completion 2027-02-28

Catalyst Primary completion. 2026-11-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Efsubaglutide Alfa group

Regimen daily

Weeks 3

Population Obesity; Weight Loss; Metabolic Surgery

control group

Regimen daily

Weeks 3

Population Obesity; Weight Loss; Metabolic Surgery

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Registry NCT07693426

Phase Phase 1

Status Recruiting

Enrollment 36

Start 2026-07-16

Primary completion 2027-04-30

Study completion 2027-08-31

Catalyst Primary completion. 2027-04-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Efsubaglutide Alfa 5 mg QW

Dose 5 mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Adolescence Obesity

Efsubaglutide Alfa 10 mg QW

Dose 10 mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Adolescence Obesity

Efsubaglutide Alfa 20 mg QW

Dose 20 mg

Regimen once weekly

Weeks 12

Comparator placebo

Population Adolescence Obesity

Efsubaglutide Alfa placebo

Regimen once weekly

Weeks 12

Population Adolescence Obesity